e-learning
resources
Copenhagen 2005
Monday 19.09.2005
CAP: aetiology and management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Barriers to adherence to key indicators of antibiotic use for community-acquired pneumonia: a qualitative study
J. A. Schouten, M. E. J. L. Hulscher, S. Natsch, J. W. M. van der Meer, R. P. T. M. Grol (Nijmegen, Netherlands)
Source:
Annual Congress 2005 - CAP: aetiology and management
Session:
CAP: aetiology and management
Session type:
Poster Discussion
Number:
1754
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. A. Schouten, M. E. J. L. Hulscher, S. Natsch, J. W. M. van der Meer, R. P. T. M. Grol (Nijmegen, Netherlands). Barriers to adherence to key indicators of antibiotic use for community-acquired pneumonia: a qualitative study. Eur Respir J 2005; 26: Suppl. 49, 1754
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Determinants of performance of indicators on antibiotic use in community-acquired pneumonia (CAP) at hospitals
Source: Eur Respir J 2005; 26: Suppl. 49, 638s
Year: 2005
Influence of adherence to clinical guidelines in empiric antibiotics choice on outcomes of community-acquired pneumonia in hospitalized Belarussian patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome
Source: Eur Respir J 2008; 32: 892-901
Year: 2008
The assessment of physicians' knowledge of community-acquired pneumonia basics: KNOCAP study
Source: International Congress 2019 – Medical education
Year: 2019
Adherence to guidelines and clinical stability in community-acquired pneumonia
Source: Eur Respir J 2004; 24: Suppl. 48, 241s
Year: 2004
Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study
Source: Eur Respir J, 54 (1) 1900057; 10.1183/13993003.00057-2019
Year: 2019
Guideline-concordant therapy and outcomes in healthcare-associated pneumonia
Source: Eur Respir J 2011; 38: 878-887
Year: 2011
The impact of adherence to guidelines for hospitalized community-acquired pneumonia on health outcomes and mortality: A retrospective cohort study
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015
Can CAP guideline adherence improve patient outcome in internal medicine departments?
Source: Eur Respir J 2008; 32: 902-910
Year: 2008
Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens
Source: Eur Respir J 2002; 20: 432-439
Year: 2002
Hospital-acquired pneumonia: coverage and treatment adequacy of current guidelines
Source: Eur Respir J 2003 Dec 01;22(6):876-882
Year: 2003
The extent of microbiological testing and antibiotic de-escalation in adults with community-acquired pneumonia: a retrospective cohort study.
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
Source: Eur Respir J 2011; 37: 1332-1339
Year: 2011
Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives
Source: Eur Respir J 2004; 24: Suppl. 48, 185s
Year: 2004
Antibiotic therapy of community-acquired pneumonia in the hospital setting: national guidelines and real clinical practice.
Source: International Congress 2017 – COPD management
Year: 2017
Validation of treatment adequacy of current guidelines for hospital-acquired pneumonia
Source: Annual Congress 2003 - Epidemiology, therapy and outcome of infections in the ICU
Year: 2003
Improving antibiotic utilisation for nosocomial pneumonia
Source: International Congress 2019 – Multidrug resistance in nosocomial pneumonia: burden, magnitude and solution
Year: 2019
Impact of guidelines on HAP and VAP outcomes
Source: Eur Respir Mon 2011; 53: 66-73
Year: 2011
Verifying the antibiotic selection algorithm in the new Japanese pneumonia guidelines - Is algorithm-discordant treatment associated with increased mortality of healthcare-associated pneumonia?
Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit
Year: 2018
The impact of a stewardship programme on outcomes in patients admitted with community-acquired pneumonia
Source: Virtual Congress 2020 – Antibiotic therapy for pneumonia and pleural infections
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept